Defining a GenAI strategy for Ophthalmology R&D

Challenge: Translating GenAI potential into actionable value

The Ophthalmology department of our client, a leading pharmaceutical company, was exploring how GenAI could transform the way treatments are discovered, developed, and optimized. The goal was to understand the real-world potential of GenAI in accelerating R&D, identifying viable opportunities, and defining a strategic GenAI blueprint for future ophthalmic analytics and decision support across verticals.

The team, however, faced uncertainty around the business impact and maturity of emerging AGI capabilities. To overcome this, we identified specific use cases GenAI can already handle and expanded them to all business verticals, clearly stating the risks, mitigation strategies, and a comprehensive timeline.

How we helped

We collaborated with the R&D and data teams to define the capabilities of multimodal and multitask embedded AI research assistants tailored for early-stage drug development in Ophthalmology. These assistants demonstrated how GenAI could enhance data interpretation, automate research synthesis, and support clinical decision-making. Additionally, we facilitated leadership alignment by effectively communicating the department’s GenAI vision, use case roadmap, and measurable business outcomes at the executive leadership level.

The Impact: Laying the foundation for scalable GenAI adoption

At Visium, we help organizations move beyond experimentation and build scalable AI strategies that drive lasting impact. This project exemplifies how a focused GenAI vision can unlock new efficiencies, inspire leadership alignment, and accelerate scientific discovery.

• 3-5% revenue growth due to adopting the GenAI vision
• Set up a strong data foundation
• Helped restore traction on data engineering efforts that had been chronically postponed